No link to cardiac valvulopathy was seen in cabergoline treated patients
<p><strong>Objective:</strong> To evaluate the association between use of cabergoline in patients with prolactinoma and risk of developing clinically relevant cardiac valvular disease.</p> <p><strong>Method:</strong> This was a descriptive cross sectional st...
Egile Nagusiak: | K Dharshini, Noel Somasundaram, HMDPK Senevirathna, S Raj Kumar |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
Sri Lanka College of Endocrinologists
2012-10-01
|
Saila: | Sri Lanka Journal of Diabetes Endocrinology and Metabolism |
Gaiak: | |
Sarrera elektronikoa: | https://sjdem.sljol.info/articles/4775 |
Antzeko izenburuak
-
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
nork: Shruti Khare, et al.
Argitaratua: (2017-01-01) -
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
nork: Annabelle G Hayes, et al.
Argitaratua: (2023-01-01) -
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
nork: Youngki Lee, et al.
Argitaratua: (2014-09-01) -
Spontaneous reduction of prolactinoma post cabergoline withdrawal
nork: Sampath Kumar Venkatesh, et al.
Argitaratua: (2012-01-01) -
The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
nork: Larisa Dzeranova, et al.
Argitaratua: (2016-11-01)